Innate Pharma (ADR) - IPHA - stock price prediction, stock price target, analyst ratings from 3 analysts

Innate Pharma (ADR) has a share price target of US$ 7, revenue growth forecast of 379.3%, and profit growth estimate of 82.3% for FY26, based on top 3 analyst calls.